Dr. Athanasios Nicholas Tiliakos, DO

Dr. Tiliakos practices at Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University.

Dr. Tiliakos' NPI, 1023270576, was assigned on June 26, 2008. Dr. Tiliakos holds Georgia license 063972.

Dr. Tiliakos' primary practice is Emory University Hospital Midtown, at 550 Peachtree Street, NE, Atlanta, GA 30308 in Fulton County. The practice phone is (404) 686-2450.

Dr. Tiliakos' primary practice is Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University. Dr. Tiliakos is also affiliated with Emory University Hospital. The medical group on file is Emory Clinic. Dmand AI also links Dr. Tiliakos to 1 more hospital, 2 group practices and clinics, 1 clinical lab and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tiliakos practices, 6 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Tiliakos' primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Tiliakos is board certified in rheumatology by the American Board of Internal Medicine. Dr. Tiliakos is licensed in Georgia.

CMS data shows 859 Medicare services from Dr. Tiliakos across 6 procedure codes in 2024, for 265 Medicare patients. Medicare paid $42,832 for them. Every service was in an office.

CMS counts 265 Medicare patients who saw Dr. Tiliakos in 2024. The largest group is 65 to 74, with 101 patients. 75% of them have arthritis, and 74% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tiliakos' median patient age at 65, with 75% women.

In 2024, Dr. Tiliakos wrote 2,850 Medicare Part D claims for 422 patients. 83% of them were for generic drugs. CMS names the drug for 2,537 of them, across 39 drugs with 11 or more claims each, at $2,837,943 in total drug cost. In 2023, CMS named 2,469 claims across 41 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Tiliakos for performance year 2024, reported through an alternative payment model (APM). Dr. Tiliakos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tiliakos as offering telehealth.

CMS Open Payments shows 10 general payments to Dr. Tiliakos from 3 drug and device companies from 2019 to 2022. Travel and lodging make up the largest share, 89% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,556.